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Abstract 
Background: New fluid biomarkers for Alzheimer’s disease (AD) that reveal synaptic and neural network dysfunc‑
tions are needed for clinical practice and therapeutic trial design. Dense core vesicle (DCV) cargos are promising 
cerebrospinal fluid (CSF) indicators of synaptic failure in AD patients. However, their value as biomarkers has not yet 
been determined.
Methods: Immunoassays were performed to analyze the secretory proteins prohormone convertases PC1/3 and 
PC2, carboxypeptidase E (CPE), secretogranins SgIII and SgII, and Cystatin C in the cerebral cortex (n = 45, provided 
by Bellvitge University Hospital) and CSF samples (n = 66, provided by The Sant Pau Initiative on Neurodegeneration 
cohort) from AD patients (n = 56) and age‑matched controls (n = 55).
Results: In AD tissues, most DCV proteins were aberrantly accumulated in dystrophic neurites and activated astro‑
cytes, whereas PC1/3, PC2 and CPE were also specifically accumulated in hippocampal granulovacuolar degeneration 
bodies. AD individuals displayed an overall decline of secretory proteins in the CSF. Interestingly, in AD patients, the 
CSF levels of prohormone convertases strongly correlated inversely with those of neurodegeneration markers and 
directly with cognitive impairment status.
Conclusions: These results demonstrate marked alterations of neuronal‑specific prohormone convertases in CSF 
and cortical tissues of AD patients. The neuronal DCV cargos are biomarker candidates for synaptic dysfunction and 
neurodegeneration in AD.
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Background
Alzheimer’s disease (AD) is the most prevalent neuro-
degenerative disorder in the elderly [1]. Because cur-
rently there is no effective treatment or prevention 
for AD, identification of AD fluid biomarkers in the 
neuropathological progression of the illness is crucial 
to clinical practice and therapeutic trial design [2–4]. 
The main clinical symptoms of AD are gradual and pro-
gressive memory and cognitive impairments, which 
strongly correlate with the cortical atrophy-related syn-
aptic and neuronal loss in all affected brain regions 
[5–7]. Pathologically, AD is characterized by deposits of 
amyloid-β (Aβ) peptides in extracellular senile plaques 
and accumulation of hyperphosphorylated tau protein in 
somatic neurofibrillary tangles and plaque-surrounding 
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dystrophic neurites. In addition to the loss of neural cir-
cuitry and neuronal cell bodies, cerebral amyloid angiop-
athy, granulovacuolar degeneration (GVD), and Hirano 
bodies with glial activation have also been suggested as 
part of AD pathology [8].
Reliable cerebrospinal fluid (CSF) signatures have been 
developed for plaque and tangle pathologies and for 
associated neurodegenerative processes (reduced Aβ1–42 
and increased phosphorylated tau (P-tau) and total tau 
(T-tau) levels, respectively). These core CSF biomarkers 
are currently routinely used in clinical practice for diag-
nosis of AD in patients at the mild cognitive impairment 
or dementia stage of the disease [9]. Additionally, several 
reports have proposed certain microglial and astrocytic 
proteins, such as TREM2 and YKL-40, as biomarkers of 
glial activation in AD [10–13]. Importantly, as decreased 
synapses are a major quantitative correlate of loss of 
memory and cognition in AD brains [7], much attention 
is being focused on biomarkers to detect the degree of 
synaptic dysfunction and degeneration in early stages of 
AD. Novel CSF biomarker candidates for synaptic pathol-
ogy include axonal and pre- and postsynaptic proteins, 
such as SNAP-25, Syntaxin 1B, neurogranin and neuro-
filament light chain [14–17].
Other potential CSF biomarkers for synaptic alterations 
in AD consist of released cargos of the so-called dense 
core vesicles (DCVs). As synaptic vesicles (SVs), DCVs 
belong to the regulated secretory pathway in neurons and 
also, presumably, in astrocytes [18, 19]. In response to 
membrane depolarization, DCVs release a variety of neu-
ropeptides and growth factors (e.g. brain-derived neuro-
trophic factor [BDNF]) as well as distinctive molecular 
components, such as chromogranins (Cg), secretogra-
nins (Sg), and processing enzymes [18]. Although DCVs 
do not accumulate within synaptic compartments as 
do SVs, the vast majority of fusion events occur at syn-
aptic boutons and axons [20, 21]. Interestingly, a major 
and ubiquitous constituent of the DCV matrix, CgA, was 
one of the first biochemical biomarker candidates for AD 
synaptic degeneration [22, 23]. Recent advances in prot-
eomic technology have identified secreted DCV proteins 
in CSF screens for AD patients, such as the prototype 
granins CgA and CgB and the non-classical granin SgVII 
(usually called VGF, the nerve growth factor inducible 
protein VGF) [24, 25]. These observations suggest that 
DCV proteins may be promising biomarkers of synaptic 
loss in AD. However, changes in DCV cargos in AD CSF 
observed in different proteomic and immunological anal-
yses offer variable results, or have not been completely 
validated [26, 27]. Here, we investigated changes in DCV 
proteins in the CSF and brain samples of AD patients. 
Specifically, we examined the neuronal prohormone con-
vertases PC1/3 and PC2, and the neuronal and astroglial 
carboxypeptidase E (CPE), SgIII and SgII [28–33]. Addi-
tionally, we examined the secretory protein Cystatin 
C (CysC), a neuronal and astrocytic protease inhibitor 
involved in AD, located mainly in lysosomes and possibly 
in DCVs [34, 35].
Materials and methods
Brain tissues
Post-mortem human AD (n = 23) and non-AD (n = 22) 
brain samples (aged 49–86) were obtained from the 
Institute of Neuropathology Brain Bank IDIBELL Hos-
pital Universitari de Bellvitge (Hospitalet de Llobregat, 
Spain) under an agreement with the local ethics commit-
tee; demographic data are presented in Table 1. Individu-
als were selected based on the post-mortem diagnosis 
of AD according to the ABC score (A, Amyloid phases 
Thal; B, Braak stages of neurofibrillary tangle pathol-
ogy; C, CERAD stages) following the National Institute 
on Aging-Alzheimer’s Association (NIA-AA) clinical 
research criteria [36]. The AD-diagnosed subjects corre-
sponded to A3-A4, V-VI (B3) and C3, whereas the non-
AD subjects were A0, 0-I/II (B0-BI) and C0.
Table 1 Demographic information for Alzheimer’s disease and control brains
F, female; M, male
Age (years) Gender Post-mortem time 
(hours)
Cortical region Type of investigation
Control (n = 3) 71.0 (± 7.0) 1M/2F 5.2 (± 2.8) Parietal cortex Immuno‑histochemistry
AD (n = 5) 78.4 (± 4.6) 5F 5.7 (± 3.8)
Control (n = 5) 69.6 (± 5.3) 3M/2F 9.3 (± 4.0) Hippocampus  Immuno‑histochem‑
istryAD (n = 4) 75.8 (± 6.5) 2M/2F 5.9 (± 2.2)
Control (n = 7) 73.7 (± 7.3) 4M/3F 6.0 (± 2.8) Parietal cortex Western blot
AD (n = 7) 80.1 (± 6.6) 2M/5F 6.3 (± 3.4)
Control (n = 7) 73.3 (± 13.1) 7M 6.6 (± 4.7) Hippocampus  Western blot
AD (n = 7) 81.9 (± 3.7) 4M/3F 6.4 (± 1.9)
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Lumbar CSF samples
Both AD patients and control subjects (healthy volun-
teers) were recruited from the SPIN cohort in the Mem-
ory Unit at the Hospital de la Santa Creu i Sant Pau [37]. 
This study was approved by the local ethics committee 
and was carried out in accordance with the Declara-
tion of Helsinki. All patients (or their nearest relatives) 
and controls gave informed consent to participate in the 
study. Extensive clinical, neuropsychological, MRI and 
molecular examinations were performed in all subjects. 
CSF samples (n = 66) were collected by lumbar punc-
ture between 9 am and noon. Centrifugation at 4  °C for 
10 min at 2000 × g and storage of 500 μl aliquots in poly-
propylene tubes at − 80 °C were accomplished within 1 h 
after collection. All AD patients fulfilled clinical criteria 
for probable AD according to the revised NIA-AA cri-
teria [38] and had a CSF biomarker profile consisting of 
decreased Aβ1-42 plus high T-tau and P-tau levels (ELISA 
tests from Innogenetics, Ghent, Belgium), indicating high 
likelihood of being due to AD. The cut-off values we used 
to define our AD cohort in this study were 550 pg/ml for 
Aβ1-42, 350 pg/ml for T-tau, and 61 pg/ml for P-tau [39]. 
The control group was defined according to the following 
criteria: objective cognitive performance within the nor-
mal range (performance within 1.5 standard deviation) 
on all tests from a specific test battery, clinical dementia 
rating scale score of 0, no significant psychiatric symp-
toms or previous neurological disease, and a non-path-
ological CSF biomarker profile. The average Mini-Mental 
State Examination (MMSE) score was 21.6 ± 4.4 for AD 
patients, whereas control subjects had a score of 28 or 
higher. AD and control groups were well matched for age 
at CSF collection. Demographic information is presented 
in Table 2.
Antibodies
Home-made and commercial antibodies against DCV 
proteins used in this study have been extensively validated 
for western blot and immunohistochemical methods in 
previous papers and recognize processed and precur-
sor molecular forms. Polyclonal antibodies against PC2 
(LS18 kindly provided by Dr I. Lindberg, University of 
Maryland) and SgII/Secretoneurin have been described 
elsewhere [40, 41]. Polyclonal antibodies against PC1/3 
were purchased from Abcam (ab3532, Abcam Plc, Cam-
bridge, UK) and Thermo (PA1-057, Thermo Fisher Sci-
entific, Waltham, MA) and polyclonal antibodies against 
PC2 were from GeneTex (GTX23533, GeneTex Inc, 
Irvine, CA) [42–44]. Polyclonal antibodies against SgIII 
(HPA006880, Prestige Antibodies® supported by The 
Human Protein Atlas) [29, 45] and monoclonal anti-β-
actin peroxidase antibodies (AC-15) were purchased 
from Sigma (Sigma-Aldrich, Diesenhofen, Germany). 
Monoclonal and polyclonal antibodies against CPE were 
obtained from BD Biosciences (610758, BD Transduction 
Laboratories, San Jose, CA) and GeneTex (GTX23533, 
GeneTex Inc), respectively [45, 46]. Polyclonal antibodies 
against CysC (ABC20) [47] and monoclonal antibodies 
against GFAP (MAB3402) were obtained from Millipore 
Iberica (Madrid, Spain). Monoclonal and polyclonal anti-
bodies against CHMP2B (MAB7509) and CK1δ (AF4568) 
were purchased from R&D Systems (Minneapolis, MN). 
Monoclonal antibodies against LAMP-1 (H4A3) and 
neurofilament light chain (2835) were obtained from 
Developmental Studies Hybridoma Bank at the Univer-
sity of Iowa (Iowa City, Iowa) and Cell Signaling (Leiden, 
The Netherlands), respectively. Antibodies against Aβ 
(M087201-2) and hyperphosphorylated tau (AT8) were 
from DAKO (Glostrup, Denmark) and Innogenetics 
(Gent, Belgium), respectively. A complete antibody list is 
provided in Additional file 1: Table S1.
Immunohistochemistry
Human brain samples were fixed in 4% paraformalde-
hyde in 0.1  M phosphate buffer, pH 7.4, by immersion. 
After being cryoprotected in a 30% sucrose solution, the 
samples were frozen and sectioned with a cryostat. For 
peroxidase immunohistochemistry, histological sec-
tions were blocked for 30  min in phosphate buffered 
saline (PBS) supplemented with 10% methanol and 3% 
 H2O2 and then washed in PBS. Pretreatment with for-
mic acid was used to enhance labeling of plaques. To 
avoid nonspecific binding, brain sections were blocked 
in PBS containing 10% serum, 0.2% glycine, 0.1% Triton 
X-100, and 0.2% gelatin for 1  h at room temperature. 
Table 2 Demographics and CSF profiles of individuals
Data are presented as mean ± SEM
***P < 0.001, Mann-Whitney test. F, female; M, male








Control (n = 33) 63.75 (± 7.18) 13M/20F 29.21 (± 0.96) ε2 = 0.05
ε3 = 0.83
ε4 = 0.12
836.09 (± 154.72) 221.97 (± 57.44) 43.38 (± 10.39) 3.46 (± 0.51)







99.33 (± 31.32)*** 3.39 (± 0.51)
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Incubations with the primary antibodies were carried 
out overnight at 4  °C in PBS containing 1% fetal bovine 
serum, 0.1% Triton X-100 and 0.2% gelatin. Bound anti-
bodies were detected using the avidin–biotin-peroxidase 
system (Vectastain ABC kit, Vector Laboratories Inc., 
Burlingame, CA). PBS containing 0.05% diaminoben-
zidine  (DAB) and 0.01%  H2O2 was used to visualize the 
peroxidase complex. Sections were mounted, dehydrated, 
and coverslipped in Eukitt® (Sigma-Aldrich, Diesen-
hofen, Germany). Semiquantitative analysis of CysC 
immunoreactivity on DAB-stained slices was carried 
out on the outer and inner layers of the AD and control 
parietal cortices (n = 3, each). Images at 20 × magnifica-
tion (2 per section, 2 sections per sample) were randomly 
taken using identical acquisition microscope parameters. 
The signal intensity of 0.1 × 0.1  mm2 fields was measured 
using the ImageJ® software (NIH,  Bethesda, MD). Lev-
els of CysC were initially quantified as arbitrary density 
units and subsequently AD values were expressed as a 
percent change from control measurement. Double-labe-
ling fluorescent immunohistochemistry was carried out 
by incubation with different fluorochrome-conjugated 
secondary antibodies (Alexa Fluor 488 and Alexa Fluor 
568; Molecular Probes, Eugene, OR), and cell nuclei were 
stained with Hoechst (Sigma-Aldrich, Diesenhofen, Ger-
many). Endogenous autofluorescence was avoided using 
Sudan Black B (Sigma-Aldrich, Diesenhofen, Germany). 
Sections were mounted in Mowiol (Merk Chemicals Ltd., 
Nottingham, UK) and visualized with a Leica TCS SPE 
scanning confocal microscope. Colocalization analyses 
of DCV proteins with GVD markers were performed by 
ImageJ software, using the threshold-corrected Mander’s 
correlation coeficient, which ranges between 1 (high-
colocalization) and 0 (low-colocalization). The specific-
ity of the immunolabeling was checked omitting primary 
antibodies, using nonspecific IgG instead of them and 
using a previous incubation of the primary antibod-
ies with an excess of antigen (Proteintech Group Inc., 
Deansgate, Manchester, UK). No immunostaining was 
observed in these conditions.
Western blotting and radioimmunoassay
Equal volumes of lumbar CSF samples were collected 
in vials and brain tissues were homogenized in ice-cold 
lysis buffer containing 50 mM Tris–HCl, pH 7.4, 150 mM 
NaCl, 5 mM  MgCl2,1 mM EGTA, 1% Triton X-100, and 
a protease inhibitor cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany). The CSF samples and postnuclear 
brain lysates were mixed with 3 × sample buffer (188 mM 
Tris–HCl, 30% glycerol, 3% SDS, 0.01% Bromophenol 
Blue, and  15% β-mercaptoethanol), electrophoresed in 
10%–12% SDS-acrylamide gel (Bio-Rad Laboratories, 
Hercules, CA), and then transferred to polyvinylidene 
difluoride immobilization membranes (Whatman® 
Schleicher & Schuell, Keene, NH). Tissue results were 
normalized for total protein content (data obtained from 
Ponceau staining scans). Membranes were blocked in 5% 
nonfat milk powder solution in Tris-buffered saline and 
Tween-20 (TBST; 140  mM NaCl, 10  mM Tris/HCl, pH 
7.4 and 0.1% Tween-20) for 1 h at room temperature and 
then incubated with primary antibodies in blocking solu-
tion overnight at 4 °C. After numerous washes in block-
ing buffer, the membranes were incubated for 1  h with 
horseradish peroxidase-conjugated secondary antibodies 
(Bio-Rad Laboratories, Hercules, CA). Enhanced chemi-
luminescence reagents ECL™ (GE Healthcare, Buck-
inghamshire, UK) and X-ray films (AGFA) were used to 
visualize bound antibodies. Blot images were taken with 
a scanner and densitometric values were obtained using 
a Java-based image processing software (ImageJ® soft-
ware). The amount of total proteins in brain homogen-
ates (10–15  µg) and CSF volume (2–5  µl) and exposure 
times of the films were empirically determined to obtain 
the adequate linear range for quantitative analysis. For 
protein forms with different electrophoretic mobilities, 
a single average exposure of the film is shown in the fig-
ures, whereas quantitative analysis of each form was per-
formed at different and suitable amounts of total protein/
volume and exposure time of the films.
The SgII/secretoneurin radioimmunoassay was per-
formed as described previously [41]. In brief, samples 
were denatured to avoid protein degradation and anti-
serum was added in the radioimmunoassay buffer and 
incubated for 24 h at 4 ºC. Then iodinated secretoneurin 
(200 cpm/μL) was added and samples were incubated for 
an additional 24 h at 4 ºC. The non-bound tracer was sep-
arated by dextran-coated charcoal absorption and pulled 
down by centrifugation. The iodinated tracer remaining 
in the supernatant fraction was quantified, with a detec-
tion limit of 1–2 fmol.
Statistical analysis
Quantitative data were statistically analyzed using 
GraphPad Prism 6.01® software (GraphPad Software, 
San Diego, CA) with t-test and Mann–Whitney test. All 
data are presented as the means ± SEM. Significance was 
set at P < 0.05. Correlations of the measured values were 
examined using the Bonferroni-corrected Spearman cor-
relation coefficient. A significance cutoff of P ≤ 0.0019 
based on Bonferroni correction of multiple comparisons 
and P ≤ 0.05 in non-corrected comparisons were applied.
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Results
DCV markers are neuropathologically accumulated 
in dystrophic neurites and GVD bodies in the AD cerebral 
cortex
To examine DCV changes in the cerebral cortex of AD 
patients, we performed Western blotting and immu-
nostaining analyses in homogenates and histological 
sections from AD patients and age-matched controls. 
PC1/3, PC2, CPE, SgIII and SgII were abundantly found 
by immunoblotting in cortical samples (Additional file 1: 
Fig. S1). In addition to the unprocessed and mature 
forms, higher and lower electrophoretic mobility bands 
were detected with polyclonal antibodies against DCV 
proteins, likely corresponding to the described aggre-
gated and cleaved species [30–32]. A robust detec-
tion for all of these proteins was noted in CSF samples, 
essentially their precursor and mature forms. Volumes as 
small as 1 µL were enough to detect some of these pro-
teins in the CSF (i.e. SgIII). As previously reported, only 
the monomeric form of the secretory protease inhibitor 
CysC was detected in the CSF (~ 14  kDa), whereas cor-
tical tissues also displayed oligomeric/aggregated spe-
cies [48, 49]. When performing analyses of similar CSF 
volumes, levels of membrane and cytosolic proteins such 
as synaptophysin (Syp) and β-actin (Additional file 1: Fig. 
S1), as well as the potential AD biomarker neurofilament 
light chain (data not shown), were under the detection 
limit. Thus, besides the abundance in brain tissues, DCV 
proteins are broadly detected in the CSF, feasibly corre-
sponding with released species.
Next, we examined the levels of distinct molecular 
forms of secretory proteins in AD brains by immunob-
lotting (n = 7 per tissue and condition) (Fig. 1 and Addi-
tional file 1: Fig. S2). Comparing DCV protein amounts 
(normalized to membrane-transferred total protein) in 
hippocampus and parietal cortex of AD cases with con-
trols, we only found changes for the 72-kDa precursor 
form of PC2 (proPC2). The proPC2 species was increased 
1.7-fold in parietal cortex (P = 0.038) and 2.4-fold in hip-
pocampus (P = 0.0006). Interestingly, the ~ 28  kDa form 
of CysC was significantly decreased in the parietal cor-
tex of AD patients (35%, P = 0.038). This electrophoretic 
band probably corresponds to dimeric or aggregated 
forms of CysC, which have been associated with amy-
loid damage [48, 49]. Finally, a prominent reduction was 
evident in the content of the SV-specific integral protein 
Syp both in parietal cortex (30%, P = 0.042) and in hip-
pocampus (50%, P = 0.017) of AD patients. These results 
Fig. 1 Levels of secretory proteins in the AD cerebral cortex. Left Representative western blots showing protein levels of PC1/3, PC2, CPE, SgIII, CysC, 
Syp, and β‑actin in homogenates of control and AD hippocampus. Each of the two immunoblotting columns illustrates levels of different proteins 
in the same cases blotted on the same membrane. The total membrane‑transferred proteins were detected by Ponceau S staining. The mobility of 
molecular mass markers (in kDa) is indicated. Right Secretory (PC1/3, PC2, CPE, SgIII, CysC) and synaptic vesicle (Syp) protein levels in the parietal 
cortex (PCx) and hippocampus (HP) of AD patients compared to the age‑matched controls (n = 7 for each tissue). Graphs show the percentage 
variation compared with controls and normalized to total membrane‑blotted proteins. Levels of the precursor form of PC2 (proPC2) were increased 
in AD cortical tissues, whereas CysC dimers/aggregates were reduced in the PCx of AD patients. A consistent decrease of Syp is detected in both AD 
cortices, HP and PCx. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, Mann–Whitney test
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show that the global levels of different DCV markers are 
mostly preserved in AD cortices, whereas ubiquitous SV 
proteins are dramatically reduced.
To examine the alterations of DCV proteins in situ, we 
performed peroxidase immunohistochemical and confo-
cal immunofluorescence analyses in brain sections from 
control (n = 8) and AD cases (n = 9). In controls, PC1/3, 
PC2, CPE, SgIII, SgII and CysC were widely distributed 
throughout the cerebral cortex, consistent with previ-
ous studies [45, 50–52] (Fig.  2). All of these proteins 
were abundant in neuronal populations of the neocor-
tex and hippocampus (Fig.  2a), although a differential 
and robust immunolabeling for CPE was detected filling 
dendritic shafts (Fig.  2a, c). Immunostaining for SgIII, 
CPE, and CysC was also detected in  GFAP+ astrocytes 
(Fig.  2b), whereas prohormone convertases were absent 
in glial cells. In neurons, subcellular structures labeled 
for secretory proteins included somatic and dendritic 
granules, varicose fibers, and terminal-like buttons, as 
we previously reported [45]. Granular compartments 
immunostained for typical DCV markers were negative 
for the lysosomal marker LAMP1 (not shown), whereas 
CysC immunofluorescence was largely associated with 
 LAMP1+ structures (Fig.  2c). Immunostaining altera-
tions for secretory proteins in AD cortices were mainly 
associated with senile plaques (Fig. 3a). All typical DCV 
components were aberrantly accumulated, to different 
degrees, in  AT8+   dystrophic neurites surrounding amy-
loid plaques, in the parietal cortex and hippocampus (in 
each examined AD cases) (representative examples are 
shown in Fig. 3b, c). In some samples, intense immunola-
beling for SgIII and CysC was detected in reactive astro-
cytes close to the amyloid deposits (data not shown), as 
described elsewhere [45, 51]. No major changes were 
detected for secretory proteins in non-plaque areas of 
the AD brains, including tangle-bearing neuronal somata 
identified by the AT8 antigen (excepting cells showing 
GVD, see below). Only a slight, but consistent, increase 
in CysC was found in pyramidal neurons located in outer 
and inner layers of the AD parietal cortex (Additional 
file 1: Fig. S3).
Unexpectedly, we found GVD-shaped structures 
immunolabelled for some DCV proteins in CA1 pyram-
idal somata (and to a lesser extent in CA2 and sub-
iculum) in each of the four examined AD hippocampi 
(Fig. 4a). These granules had strong immunostaining for 
PC2 and moderate immunostaining for PC1/3, whereas 
only one AD case displayed scarce  CPE+ large granules 
(Fig.  4a). An average of 241 ± 4 CA1 pyramidal neu-
rons containing aberrant  PC2+ granules per  mm2 was 
observed in AD (n = 4), whereas age-matched controls 
were virtually devoid of these (a few cells, and in only 1 
out of 5 cases). Double labeling of PC1/3, PC2 or CPE 
and the established GVD markers CK1δ and CHMP2B 
Fig. 2 Distribution of secretory proteins in the control cerebral cortex. a Peroxidase immunohistochemistry shows distribution of representative 
secretory proteins (PC1/3, PC2, CPE, SgIII and CysC) in the CA1 region of the hippocampus. Scale bar, 20 μm. b Peroxidase immunohistochemistry 
and double confocal immunofluorescences illustrating SgIII (grey matter), CPE and CysC (white matter) in neocortical astrocytes. Arrowheads 
indicate glial soma and projections. Scale bars, 10 μm. c Double immunofluorescences of two different neocortical pyramidal neurons showing 
CysC colocalization with the lysosomal marker LAMP1, but not with the DCV cargo CPE. Scale bars, 5 μm
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substantiated the neuropathological identity of these 
large granules (Fig. 4b). Mander’s correlation coefficient 
for CK1δ overlapping with PC2 was 0.55 ± 0.13 and for 
PC2 overlapping with CK1δ was 0.62 ± 0.20 (n = 12), 
whereas Mander’s coefficient for CHMP2B overlapping 
with PC1/3 was 0.43 ± 0.25 and for PC1/3 overlapping 
with CHMP2B was 0.54 ± 0.28 (n = 10). These values 
indicate good colocalization between DCV proteins 
and GVD bodies in the AD hippocampus. Additionally, 
an atypical colocalization of PC2 and PC1/3 with the 
lysosomal marker LAMP1 was also detected in GVD 
bodies (Fig.  4b). Interestingly, the PC2- and PC1/3-
immunolabelled GVD inclusions were associated with 
neurofibrillary tangle pathology in AD samples (Fig. 4c, 
d). Most pyramidal neurons displaying GVD bodies 
positive for PC2 (81%) and PC1/3 (77%) also contained 
hyperphosphorylated tau  (AT8+). Although the GVD 
inclusions positive for DCV proteins were detected in 
Fig. 3 Distribution of secretory proteins in the AD cerebral cortex. a Representative peroxidase immunohistochemistry for different secretory 
proteins in senile plaques at the superficial layers of the AD parietal cortex. Dystrophic neurite‑like structures are indicated by arrows. Scale bar 
20 µm. b In the same cortical senile plaques, AT8 immunofluorescence reveals  PC2+ and SgIII aberrant structures as dystrophic neurites. Arrows 
indicate colocalization in yellow. Scale bar, 20 µm. c Three different double immunofluorescence images showing focal Aβ+ deposit surrounded 
by positive SgIII and CPE accumulations and the presence of SgIII and CPE in the same aberrant structures. Arrows indicate colocalization in yellow. 
Scale bar 20 µm
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neurons containing mature neurofibrillary tangles, the 
DCV-labeled aberrant granules were more often pre-
sent in early-stages of  neurofibrillary tangle formation 
(Fig. 4c, d).
Taken together, these results show that an aberrant 
accumulation of DCV components is associated with 
two neuropathological hallmarks of the AD cerebral 
cortex, plaque-related dystrophic neurites and GVD 
bodies.
Decreased levels of secretory DCV cargos in CSF from AD 
patients are associated with neurodegeneration markers
Next, we investigated the levels of DCV proteins in 66 
CSF samples from phenotypically well-characterized AD 
patients (n = 33) and cognitively normal controls (n = 33) 
with immunoblotting and radioimmunoassay methods. 
No differences in the CSF total protein content were 
found between AD and controls, either by Bradford assay 
or Coomassie staining of SDS-PAGE gels (Fig. 5a). How-
ever, levels of most molecular forms of DCV proteins 
were decreased in the CSF from AD patients compared 
with those from cognitively normal controls (Figs.  5b 
Fig. 4 DCV proteins are accumulated in GVD bodies in CA1 pyramidal neurons of AD patients. a Peroxidase immunolabelling shows PC2, PC1/3 
and CPE accumulations in aberrant granules (arrowheads) located in CA1 pyramidal neurons of AD hippocampus. Scale bars, 10 μm. b PC2, PC1/3 
and CPE colocalization with the markers of GVD bodies CK1δ and CHMP2B (arrows) and the presence of lumenal PC2 and the transmembrane 
LAMP1 in the same AD granule (open‑arrows) in different neuronal cell bodies of AD cases. Scale bars, 2 μm. c  PC2+ GVD inclusions are found 
either in mature  (AT8++) (cell at left) or in undeveloped  (AT8+) (cell at right) neurofibrillary tangles in CA1 pyramidal neurons of an AD case. Scale 
bar, 7 μm. d Graphs showing the percentages of cells displaying absent (0), few (< 10), or many (≥ 10) PC2‑ and PC1/3‑labelled GVD in AD cases, 
depending on the occurrence of neurofibrillary tangles (negligible,  AT8−; low,  AT8+, strong,  AT8++)
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and 6). Representative immunoblots for different secre-
tory proteins of the same AD and non-AD individuals 
are illustrated in Fig. 5b. The most prominent reduction 
in AD was found for unprocessed PC1/3 (− 42% ± 5.7%, 
P = 0.0003). Although levels of the mature form were 
apparently lower in AD, they did not reach statistical 
significance (P = 0.075) (Fig.  6). When we quantified 
the levels of mature and unprocessed forms of PC1/3 
together, a significant decrease was detected in the AD 
group (− 24%, P = 0.03). Consistently, we also detected an 
apparent PC1/3 cleaved form displaying a lower electro-
phoretic mobility identified by the polyclonal antibodies 
used in this study. When analyzing this molecular species 
together with the other two bands, we found decreased 
levels of total PC1/3 in the CSF from AD patients com-
pared to controls (P = 0.05). In addition, each of the two 
bands detected by PC2 antibodies that represent precur-
sor and mature forms, was statistically decreased in AD 
samples (− 16%, P = 0.024 and − 12%, P = 0.011, respec-
tively; Fig. 6), as well as in a pooled quantification (− 18%, 
P = 0.0009). The DCV-contained exopeptidase CPE 
was reduced by ~ 20% in the CSF of the patient cohort 
(P = 0.016). Regarding members of the granin family, 
the most abundant form of SgIII in the CSF, proSgIII, 
was decreased in AD (P = 0.047), whereas no significant 
differences were detected for the processed protein. An 
analysis of the two forms showed no differences between 
AD and non-AD individuals (P = 0.612). We also deter-
mined the CSF levels of SgII/secretoneurin with an radio-
immunoassay assay. No statistical differences were found 
between AD and control groups. Finally, a reduction of 
about 33% was observed for the secretory protein CysC 
in the CSF of AD patients (P = 0.001).
To investigate the possible relationships of secretory 
protein forms with age, cognitive status (MMSE), and the 
core CSF biomarkers of AD (Aβ1–42, P-tau and T-tau), 
Spearman correlation analysis was carried out in the AD 
cohort (33 individuals) (Fig.  7). No molecular forms of 
secretory proteins were significantly correlated with age 
or Aβ1–42 (Fig. 7). In contrast, we detected strong correla-
tions, positive between the mature PC2 form and MMSE 
score (P = 0.0001, r = 0.6449) and inverse between PC2 
and T-tau (P = 0.0004, r =  − 0.5837), applying Bonferroni 
correction. Non-corrected analysis further evidenced 
an inverse correlation of P-tau with PC2 and PC1/3 and 
T-tau with PC1/3, and a direct correlation of MMSE 
with PC1/3. Additionally, corrected analysis evidenced 
positive correlations between levels of P-tau and CPE 
(P = 0.0013, r = 0.5377) and the precursor form of SgIII 
(P = 0.0019, r = 0.5216), whereas non-corrected analysis 
Fig. 5 Western blot analysis of secretory proteins in the CSF of AD patients. a Total protein content in control and AD CSF samples was determined 
by Bradford assay and Coomassie staining of SDS‑PAGE gels. b Representative immunoblots show levels of PC1/3, PC2, CPE, SgIII, and CysC in the 
same control or AD CSF samples. Arrows and arrowheads indicate unprocessed and mature protein forms, respectively, and the symbol > points to 
a lower‑electrophoretic‑mobility form
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showed a direct correlation of levels of CPE, CysC and 
different forms of SgIII with P-tau and T-tau (Fig. 7).
Discussion
The present findings show that the levels of neuronal pro-
hormone convertases and other DCV proteins decrease 
in the CSF of AD patients, and that this decrease cor-
relates both with the cognitive impairment status and 
with established CSF neurodegenerative markers. In AD 
brains, these proteins accumulate in plaque-surround-
ing dystrophic neurites and reactive astroglia, whereas 
PC1/3, PC2 and CPE are also remarkably accumulated in 
hippocampal GVD bodies.
In contrast to the global loss of major SV components 
(e.g. Syp and Rab3A) [53, 54], we show that the total 
levels of DCV proteins remain mostly invariable in the 
cerebral cortex of AD patients. Only proPC2 shows a reli-
able increase in AD samples, mainly in the hippocampus. 
Fig. 6 CSF samples from AD patients display decreased levels of secretory proteins. PC1/3, PC2, CPE, SgIII and CysC were analyzed with Western 
blot and SgII with radioimmunoassay. Scatter dot‑plots represent percent variation of secretory protein levels in the CSF of AD patients (n = 33) 
compared to controls (n = 33). Data are presented as the mean ± SEM of analysis. Statistically significant difference was calculated using a two‑tailed 
Mann–Whitney test
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These observations support our previous data by Plá et al. 
[45] on SgIII and CPE, but differ from others [25, 52, 55]. 
Yakovleva et al. [55] have reported an increase in the PC2 
form in AD parietal cortex, whereas no changes of PC1/3 
and PC2 or decrease of PC1/3 has been shown in the 
injured frontal cortex [25, 52]. Because SV markers are 
virtually restricted to presynaptic terminals, their global 
alterations likely reflect variations in synaptic contacts. 
However, the broad distribution of DCV proteins makes 
it impossible to associate their total levels with synaptic 
changes. In fact, in  situ immunodetection (Figs.  2, 3, 4) 
reveals dramatic alterations of these markers at cellular 
and subcellular levels that are hidden in global analyses 
(Fig. 1 and Additional file 1: Fig. S2).
In the AD cerebral cortex, we found no apparent 
changes in DCV proteins in normal-shaped axons and 
terminal-like buttons. However, we detected accumula-
tions of DCV cargos in somata and projections of neu-
rons and astrocytes associated with the degenerative and 
inflammatory progression of the disease. Remarkably, we 
detected deposits of DCV components (mainly PC2 and 
PC1/3) in GVD bodies in pyramidal neurons in AD brain. 
These inclusions are believed to be aberrant lysosomes, 
exhibiting a central dense core, located in neurons of hip-
pocampus and other brain areas in patients with different 
primary tauopathies, especially in AD [56–58]. Our 
results showing LAMP1-surrounded  PC2+ inclusions 
in cells that contain immature neurofibrillary tangles 
are consistent with the idea that the emergence of GVD 
granules precedes the appearance of fully-formed tan-
gles in degenerating neurons [56]. To our knowledge, the 
present study is the first to provide evidence of a DCV 
cargo in these neuropathological granules. A plethora of 
proteins has been identified in GVD bodies [56, 59–61], 
including cytoskeletal components and proteins of the 
unfolded protein response, autophagic and transduc-
tion pathways, cell stress and apoptosis, the necrosome 
complex, and the RNA-binding proteins, but not DCV 
components. Therefore, our results involve the regu-
lated secretory pathway in AD-related GVD. This is sup-
ported by reports showing the presence of the SV protein 
TMEM230, the Golgi apparatus Golgin A4, and com-
ponents of the endoplasmic reticulum unfolded protein 
response in GVD bodies [56, 61–63]. Because in addition 
to the hippocampus, the parietal cortex can also display 
GVD [58], our results of elevated levels of the precur-
sor form of PC2 in AD homogenates point to non-pro-
cessed PC2 as the main form in GVD bodies, which may 
be related to the high tendency of proPC2 to form large 
aggregates [64].
Fig. 7 Correlation analysis of CSF secretory proteins with age, cognitive performance, and core CSF biomarkers in AD subjects. Top Table 
summarizing Bonferroni‑corrected Spearman correlations of secretory protein forms with age, MMSE score, Aβ1–42, P‑tau, and T‑tau. Significant 
correlations (P < 0.0019) are highlighted in green. Non‑corrected significant correlations (P < 0.05) are highlighted in yellow. Bottom Significant 
correlations are represented in scatter plots
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Another neuronal degenerative structure displaying 
prominent alteration of DCV cargos is the dystrophic 
neurite. Since the report of striking amounts of CgA in 
AD dystrophic neurites, almost every DCV marker has 
been detected as accumulating in these degenerative 
structures, including transmitter cargos (e.g. BDNF) and 
intrinsic molecular machinery (i.e. granin family mem-
bers) but not SV components [22, 45, 50, 54, 65–67]. 
In this study, we show the previously unrevealed accu-
mulation of PC1/3 and PC2 in amyloid-surrounding 
dystrophic neurites. Thus, dystrophic neurites are a sig-
nificant location for DCV retention. The recent work of 
Sadleir et  al. [68] showing a dramatic microtubule and 
trafficking disruption in dystrophic neurites associated 
with amyloid plaques strongly substantiates the aber-
rant accumulation of DCVs in these swollen structures 
and, therefore, suggests an important impairment in their 
vesicular cargo release. Lastly, in addition to the neuronal 
changes, the increased immunostaining of SgIII and 
CysC in peri-plaque astrocytes is consistent with previ-
ous studies and likely corresponds with transcriptional 
changes in activated cells and/or an Aβ-induced defi-
ciency in glial secretion [29, 33, 45, 51, 69].
In the CSF of AD patients, we detected that five out of 
the six analyzed proteins are significantly lowered com-
pared with controls. Decreased levels of PC1/3, PC2 and 
SgIII have very recently been found in large-scale pro-
teomic CSF screens from AD patients, but this has not 
been immunologically verified yet [24, 70–74], whereas 
variable results for CysC, CPE and SgII have been 
obtained [24, 71, 75–78]. In general, decreased levels of 
different DCV cargos (i.e. CgA, VGF and 7B2) have been 
found in AD CSF, with only a few reports showing oppos-
ing results [26, 78]. Several explanations might be offered 
for these discrepancies. First, the work of Duits et al. [78], 
illustrating high levels of CgA, SgII and VGF in CSF of 
patients with mild cognitive impairment progressing to 
AD, suggests that early events in the AD pathophysiolog-
ical cascade can display opposite changes in DCV cargos 
in later stages. This agrees with earlier studies showing 
that the synaptic decline in early stages of AD is com-
pensated by an increase in synaptic size of the remaining 
contacts [5]. Therefore, failure in peptidergic neurotrans-
mission, presumably occurring in dystrophic neurites, 
could trigger compensatory production of DCVs in unaf-
fected terminals. In addition, taking into account that 
cargos such as CPE, SgIII and CysC are robustly pro-
duced by neurons and non-neuronal cells, CSF levels 
could depend on the balance between neuronal impair-
ment and glial activation in different AD stages.
Since the CSF likely reflects the composition of the 
extracellular milieu in the central nervous system, 
decreased levels of secretory proteins in the CSF of 
patients could contribute to the pathophysiology of 
the disease. Based on experimental evidence, low lev-
els of neuroactive peptides, such as VGF and BDNF, 
may contribute to memory and cognitive impairments, 
whereas decreased levels of CysC and the prohormone 
convertase-binding proteins 7B2 and proSAAS could 
promote amyloidogenesis [34, 66, 67, 79, 80]. Several 
mechanisms may be put forward to underlie the occur-
rence of low concentrations of secretory proteins in 
AD CSF. Although alterations in the blood–brain bar-
rier and in extracellular peptide degradation cannot 
be ruled out, both transcriptional changes and release 
impairments may underlie the decline of secretory 
components in AD CSF [25, 33, 68, 81–83]. Addition-
ally, the decreased levels of DCV proteins in AD CSF 
may reflect the synaptic and neuronal loss occurring in 
the disease. The present results of robust inverse cor-
relation of the neuronal prohormone convertases with 
tauopathy markers and cognitive impairment strongly 
suggest that the reduced levels of these DCV cargos 
correspond with the spreading neural damage. Con-
versely, the levels of proteins expressed by both neu-
rons and astrocytes (e.g. SgIII) directly correlate with 
neurodegeneration markers in AD. Within the AD 
cohort, besides impairment of the neuronally produced 
forms, it is conceivable that production of secretory 
proteins by activated astrocytes increases as neuronal 
damage worsens [29, 45, 51, 69]. Furthermore, the con-
nection of secretory proteins with neurodegeneration, 
but not with amyloid plaque pathology, is consistent 
with recent proteomic studies in non-AD neurode-
generative diseases, such as frontotemporal dementia, 
where a decline of CgA, VGF and CysC occurs in the 
CSF of patients [84–86].
The current diagnosis methods for AD include cog-
nitive tests, neuroimaging techniques and CSF assays. 
However, there is still no clinical strategy available for 
the precise and early detection of AD. Some limitations 
involve disease heterogeneity, co-morbidities and over-
lapping between different neurodegenerative disorders 
[87]. Among new potential biomarkers, those that moni-
tor synaptic alterations are needed for prognosis of dis-
ease progression and evaluation of effects of drugs on AD 
[88]. Because the altered DCV proteins in CSF have been 
implicated in synaptopathies beyond neurodegenerative 
diseases, such as delirium and schizophrenia [89, 90], 
DCV cargos could be used as complementary biomarkers 
to follow synaptic dysfunction and loss and neurodegen-
eration in AD.
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Conclusions
The current results show alterations of DCV cargos 
belonging to regulated secretory pathways, in the CSF 
and cortical tissues of AD patients. Because neuron-
specific PC1/3 and PC2 are associated with tauopathy 
and cognitive impairment, we propose these proteins as 
complementary biomarker candidates for tracking AD-
associated synaptic dysfunction and neurodegeneration.
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